TY - JOUR A2 - Hogge, Donna AU - Chokr, Nora AU - Patel, Rima AU - Wattamwar, Kapil AU - Chokr，Samer PY - 2018 DA - 2018/11/01 TI -免疫抑制剂检查站时代的上升在骨髓增生异常综合征SP - 2458679六世- 2018 AB -骨髓增生异常综合征(MDS)是一个异质群体的疾病特点是无效造血作用和广泛的表现从懒洋洋的,无症状的血球减少急性myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy. SN - 1687-9104 UR - https://doi.org/10.1155/2018/2458679 DO - 10.1155/2018/2458679 JF - Advances in Hematology PB - Hindawi KW - ER -